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Background: Long-term opioid use for chronic non-cancer pain has increased substantially 
in recent years despite the paucity of strong supporting scientific data and concerns regarding 
adverse effects and potential misuse. 
Study Design: Review and summary of practice guidelines available on PubMed and 
Cochrane databases as well as on the Internet on chronic opioid therapy from June 2004 to 
June 2013.
Objective: To review expert-developed practice guidelines on chronic opioid therapy, published 
in different countries over the past decade in order to reveal similar principles of therapy and 
to provide useful information and references for future development of opioid guidelines to 
identify adequately supported practice points and areas in need of further scientific evidence. 
Method: Seven guidelines were identified as pertaining specifically to the long-term use of 
opioids for general chronic non-cancer pain from an initial search of the PubMed/Medline 
and Cochrane databases using combinations of the search terms “opioid,”  “chronic opioid 
therapy,” “chronic pain,” “chronic non-cancer pain,” “chronic non-malignant pain,” 
“guidelines,” “practice guidelines,” and “clinical practice guidelines,” filtered to include only 
articles on humans published in the English language over the past 10 years.
Results: All guidelines espouse an individual approach to management, beginning with a 
comprehensive patient evaluation, with particular focus on eliciting factors that may indicate 
potential drug misuse and abuse, and a trial of therapy to determine the course of treatment. 
Goals of treatment should be adequately discussed with and consented to by the patient. 
Opioids are generally not recommended as first-line therapy but, when used, clinicians should 
closely monitor patients for loss of response, adverse effects or aberrant behavior, and revise 
the treatment plan accordingly. Urine drug testing (UDT) may be used as a tool to monitor for 
aberrant behavior or drug misuse; opioid rotation may be considered when loss of response or 
adverse effects are a concern, at a starting dose lower than the calculated equianalgesic dose. 
Limitations: Information on some African nations, countries in the Middle-East, and Pacific 
Islands is not available and therefore was not included in this review.
Conclusion: There is a growing body of scientific evidence to support opioid use in chronic 
pain. Future work should focus on continuing to generate good-quality evidence on the long-
term benefits of opioid therapy, as well as scientific data to guide drug choice and dosing for 
specific conditions, populations, and situations.
Key words: Chronic pain, opioid, non-cancer pain, guidelines, opioid rotation, pain 
management, opioid therapy
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“chronic non-malignant pain,” “guidelines,” “practice 
guidelines,” and “clinical practice guidelines,” filtered 
to include only articles on humans published in the 
English language over the past 10 years, supplemented 
by a secondary Web search using the same search pa-
rameters and a manual search of listed references. In 
cases where there was more than one edition of the 
guideline within the specified duration parameters, the 
most updated version was used. Published guidelines 
not developed or supported by duly recognized spe-
cialty organizations or relevant government agencies 
were excluded from the discussion. 
Results
The clinical practice guidelines included in this re-
view were developed by the following:
•	 American	Pain	Society–American	Academy	of	Pain	
Medicine	(APS-AAPM)	(17)
•	 Australian	and	New	Zealand	College	of	Anaesthe-
tists	(ANZCA)	(18)
•	 National	 Opioid	 Use	 Guideline	 Group	 (NOUGG,	
Canada)	(19)
•	 British	Pain	Society	(20)
•	 American	 College	 of	 Occupational	 and	 Environ-
mental	Medicine	(ACOEM)	(21)
•	 American	Society	of	Interventional	Pain	Physicians	
(ASIPP)	(22)
•	 Pain	Association	of	Singapore	(23)
In general, the practice guidelines are in agreement 
with regard to the overarching principles governing the 
appropriate and responsible long-term use of opioids 
for chronic non-cancer pain. These include thorough 
patient evaluation, judicious opioid dosing, and care-
ful patient monitoring to minimize the risks of adverse 
events and abuse, while providing patients in need 
with broader options for relief from persistent pain 
and improved quality of life. Slight variations between 
guidelines arise mainly from different approaches to 
the organization and focus of each guideline, which 
may highlight different aspects of therapy in varying 
degrees. The highlights of each guidance document are 
discussed in turn below.
American Pain Society–American Academy of 
Pain Medicine (APS-AAPM)
Due to the substantial increase in the use of opi-
oid prescription in non-cancer pain despite a lack of 
support	 from	 strong	 scientific	 evidence,	 the	 APS	 and	
Despite the limited availability of strong scientific evidence to support long-term opioid therapy for chronic non-cancer pain 
(1),	use	of	opioids	has	 increased	substantially	through	
the years, with a corresponding increase in drug-
related	deaths	and	misuse	(2-8).	The	addictive	nature	of	
opioids, in addition to their psychotropic effects, makes 
them	particularly	vulnerable	to	misuse	and	abuse	(9).	By	
2007,	abuse	of	prescription	drugs	in	the	United	States	
had already surpassed that of traditionally abused 
drugs such as cocaine, methamphetamine, and heroin 
(10).	Prescription	drug	abuse	is	also	being	increasingly	
reported in other parts of the world, including parts 
of	 Africa,	 South	 Asia,	 and	 Europe	 (10).	 Global	 data	
indicate that the average opioid/morphine equivalent 
consumption	increased	from	1.82 mg/person	in	1980	to	
61.66	mg/person	in	2011	(11).
Although	various	risk	factors	have	been	identified	
for opioid misuse, environmental exposure appears to 
be the most important contributor to the increase in 
illicit	 use	 (12,13).	 In	 addition	 to	 the	 inherent	 risks	 of	
opioid tolerance, opioid-induced hyperalgesia, and 
other	 side	 effects	 (14)	 associated	with	 chronic	 opioid	
therapy, including opioid induced respiratory depres-
sion and death, unsupervised use can lead to addiction 
and its attendant physical, social, and economic adverse 
consequences, including increased suicide rate, rob-
bery, counterfeit drugs, and increased health care costs 
due to suicide, overdose, and drug abuse treatment 
(10,15,16).
In the face of the growing concerns associated 
with chronic opioid therapy, care must be taken to not 
deprive patients with a legitimate need for pain relief 
afforded by opioid analgesics. This has led to the de-
velopment of documents aimed at providing guidance 
for the responsible and appropriate use of opioids in 
chronic non-cancer pain. This article aims to provide use-
ful information and references for future development 
of opioid guidelines by reviewing expert-developed 
practice guidelines on chronic opioid therapy for non-
cancer pain, to identify adequately supported practice 
points and areas in need of further scientific evidence. 
Methods
Seven guidelines were identified as pertaining 
specifically to the long-term use of opioids for general 
chronic non-cancer pain from an initial search of the 
PubMed/Medline and Cochrane databases using combi-
nations of the search terms “opioid,”  “chronic opioid 
therapy,” “chronic pain,” “chronic non-cancer pain,” 
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the	 AAPM	 commissioned	 the	 Oregon	 Evidence-based	
Practice Center to review available evidence and de-
velop recommendations on the use of opioid therapy in 
chronic non-cancer pain. The guidance document was 
published	 in	 2009	 and	 comprised	 25	 evidence-based	
recommendations that provide guidance not only on 
the evaluation and management of patients in chronic 
pain, but also on risk mitigation and related public 
health	policies	(Table	1).		
Recommendations were graded based on methods 
adapted	from	the	Grading	of	Recommendations	Assess-
ment,	Development,	and	Evaluation	(GRADE)	Working	
Group	(24).	Each	recommendation	received	a	separate	
grade for the strength of the recommendation (strong 
Table 1. APS-AAPC guideline for the use of  chronic opioid therapy (COT) in chronic non-cancer pain (CNCP).
Area Recommendation
Strength of  
recommendation 
Quality 
of  
evidence 
Patient selection 
and risk 
stratification
1.1 Before initiating COT, clinicians should conduct a history, physical examination 
and appropriate testing, including an assessment of risk of substance abuse, misuse, or 
addiction.
Strong Low
1.2 Clinicians may consider a trial of COT as an option if CNCP is moderate or severe, 
pain is having an adverse impact on function or quality of life, and potential therapeutic 
benefits outweigh or are likely to outweigh potential harms.
Strong Low
1.3 A benefit-to-harm evaluation including a history, physical examination, and 
appropriate diagnostic testing, should be performed and documented before and on an 
ongoing basis during COT.
Strong Low
Informed consent 
and opioid 
management 
plans
2.1 When starting COT, informed consent should be obtained. A continuing discussion 
with the patient regarding COT should include goals, expectations, potential risks, and 
alternatives to COT.
Strong Low
2.2 Clinicians may consider using a written COT management plan to document 
patient and clinician responsibilities and expectations and assist in patient education. Weak Low
Initiation and 
titration of COT
3.1 Clinicians and patients should regard initial treatment with opioids as a therapeutic 
trial to determine whether COT is appropriate. Strong Low
3.2 Opioid selection, initial dosing, and titration should be individualized according to 
the patient’s health status, previous exposure to opioids, attainment of therapeutic goals, 
and predicted or observed harms. 
There is insufficient evidence to recommend short-acting versus long-acting opioids, or 
as-needed versus around-the-clock dosing of opioids.
Strong Low
Methadone 4.1 Methadone is characterized by complicated and variable pharmacokinetics and 
pharmacodynamics and should be initiated and titrated cautiously, by clinicians 
familiar with its use and risks.
Strong Moderate
Monitoring 5.1 Clinicians should reassess patients on COT periodically and as warranted by 
changing circumstances. Monitoring should include documentation of pain intensity 
and level of functioning, assessments of progress toward achieving therapeutic goals, 
presence of adverse events, and adherence to prescribed therapies.
Strong Low
5.2 In patients on COT who are at high risk or who have engaged in aberrant drug-
related behaviours, clinicians should periodically obtain urine drug screens or other 
information to confirm adherence to the COT plan of care.
Strong Low
5.3 In patients on COT not at high risk and not known to have engaged in aberrant 
drug-related behaviours, clinicians should consider periodically obtaining urine drug 
screens or other information to confirm adherence to the COT plan of care.
Weak Low
High-risk patients 6.1 Clinicians may consider COT for patients with CNCP and history of drug abuse, 
psychiatric issues, or serious aberrant drug-related behaviours only if they are able to 
implement more frequent and stringent monitoring parameters. In such situations, 
clinicians should strongly consider consultation with a mental health or addiction 
specialist.
Strong Low
6.2 Clinicians should evaluate patients engaging in aberrant drug-related behaviours for 
appropriateness of COT or need for restructuring of therapy, referral for assistance in 
management, or discontinuation of COT.
Strong Low
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or	weak)	and	for	the	quality	of	evidence	(high,	moder-
ate,	or	low).	In	general,	a	strong	recommendation	was	
based on the assessment that potential benefits of fol-
lowing the recommendation clearly outweigh potential 
harms and burdens; a weak rating was based on the as-
sessment of a tighter balance of benefits vis-à-vis harms 
or burdens, or weaker evidence. 
Of	 all	 the	 recommendations	 in	 the	 guideline,	
none were supported by high-quality evidence, and 
most	of	the	evidence	was	graded	low-quality.	Never-
theless, it was determined that the potential benefits 
of the recommendations outweigh the possible risks, 
and most of the recommendations were graded as 
strong.
Australian and New Zealand College of 
Anaesthetists (ANZCA)
The	2010	guidance	from	the	ANZCA	is	a	brief	docu-
ment outlining recommended principles in prescribing 
opioid analgesics and managing patients with chronic 
non-cancer pain based on a review of evidence, out-
lined as follows:
Area Recommendation
Strength of  
recommendation 
Quality 
of  
evidence 
Dose escalations, 
high-dose opioid 
therapy, opioid 
rotation, and 
indications for 
discontinuation of 
therapy
7.1 When repeated dose escalations occur in patients on COT, clinicians should 
evaluate potential causes and reassess benefits relative to harm. Strong Low
7.2 In patients who require relatively high doses of COT, clinicians should evaluate for 
unique opioid- related adverse effects, changes in health status, and adherence to the 
COT treatment plan on an ongoing basis, and consider more frequent follow-up visits.
Strong Low
7.3 Clinicians should consider opioid rotation when patients on COT experience 
intolerable adverse effects or inadequate benefit despite dose increases. Weak Low
7.4 Clinicians should taper or wean patients off COT who engage in repeated aberrant 
drug-related behaviours or drug abuse/diversion, experience no progress toward 
meeting therapeutic goals, or experience intolerable adverse effects.
Strong Low
Opioid-related 
adverse effects
8.1 Clinicians should anticipate, identify, and treat common opioid-associated adverse 
effects. Strong Moderate
Use of 
psychotherapeutic 
cointerventions
9.1 As CNCP is often a complex biopsychosocial condition, clinicians who prescribe 
COT should routinely integrate psychotherapeutic interventions, functional restoration, 
interdisciplinary therapy, and other adjunctive non-opioid therapies.
Strong Moderate
Driving and work 
safety
10.1 Clinicians should counsel patients on COT about transient or lasting cognitive 
impairment that may affect driving and work safety. Patients should be counselled not 
to drive or engage in potentially dangerous activities when impaired or if they describe 
or demonstrate signs of impairment.
Strong Low
Identifying a 
medical home and 
when to obtain 
consultation
11.1 Patients on COT should identify a clinician who accepts primary responsibility 
for their overall medical care. This clinician may or may not prescribe COT, but should 
coordinate consultation and communication among all clinicians involved in the 
patient’s care.
Strong Low
11.2 Clinicians should pursue consultation, including interdisciplinary pain 
management, when patients with CNCP may benefit from additional skills or resources 
that they cannot provide.
Strong Moderate
Breakthrough 
pain
12.1 In patients on around-the-clock COT with breakthrough pain, clinicians may 
consider as-needed opioids based upon an initial and ongoing analysis of therapeutic 
benefit versus risk.
Weak Low
Opioids in 
pregnancy
13.1 Clinicians should counsel women of childbearing potential about the risks and 
benefits of COT during pregnancy and after delivery. Clinicians should encourage 
minimal or no use of COT during pregnancy, unless potential benefits outweigh risks. If 
COT is used during pregnancy, clinicians should be prepared to anticipate and manage 
risks to the patient and newborn.
Strong Low
Opioid policies 14.1 Clinicians should be aware of current federal and state laws, regulatory guidelines, 
and policy statements that govern the medical use of COT for CNCP. Strong Low
Table 1 (cont.). APS-AAPC guideline for the use of  chronic opioid therapy (COT) in chronic non-cancer pain (CNCP).
CNCP = chronic non-cancer pain; COT = chronic opioid therapy
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Comprehensive assessment of the patient. 
Non-somatic	 contributions	 to	 the	 condition,	 espe-
cially the social environment, including work, must be 
recognized and addressed without ignoring the biologi-
cal contributions; patient’s attitudes regarding prognosis 
and diagnosis, and impact on daily living, relationships, 
and life events, must be explored and assessed. 
Adequate trial of other therapies. 
Drug therapy must be used mainly for symptom 
control, and as part of a multimodal approach that 
also includes non-drug therapies (e.g., patient educa-
tion,	exercise	programs,	sleep	hygiene).	Paracetamol	is	
preferred over nonsteroidal anti-inflammatory drugs 
(NSAIDs)	as	first-line	pharmacotherapy,	especially	when	
inflammation is not the relevant mechanism; adjuvant 
analgesics (e.g., tricyclic antidepressants, serotonin-nor-
adrenaline	reuptake	inhibitors,	anticonvulsants)	should	
be considered before opioids.
Agreement regarding an opioid trial. 
A	 therapeutic	 contract	 to	 define	 the	 goals	 of	
an opioid trial should be discussed and established 
between the doctor and patient, including possible 
discontinuation if the goals are not met. There should 
be only one prescriber of the patient’s opioids, with 
provision of adequate back-up should the prescriber 
become unavailable. If possible, only one pharmacy 
should dispense the opioid. 
Conduct of an opioid trial. 
Chronic pain should not be treated with short-
acting drugs. Long-acting or sustained-release oral or 
transdermal preparations are preferred. Continuous 
assessment	of	 the	 5As	 (analgesia,	 activity,	 adverse	 ef-
fects,	 affect,	 aberrant	 behavior),	 with	 corresponding	
dose titration, is recommended. Doses requiring 120 
mg morphine or equivalent warrant reassessment and 
possible specialist advice.
Response to difficulty. 
In	achieving	goals	of	an	opioid	trial.	Opioid	rota-
tion	may	be	considered	when	achieving	the	5A	assess-
ments proves difficult. Variations in stability of dose 
and responsiveness warrant comprehensive reassess-
ment	–	possible	actions	include	recalibration	of	goals	of	
therapy, tapering of opioid to withdrawal, reconsidera-
tion of other modes of therapy, and consultation with 
colleagues.
The above recommendations are, in the main, 
consistent with the principles governing the recom-
mendations in the rest of the guidelines discussed in 
this article, and appear to be a distillation of the South 
Australian	 guideline	 published	 in	 2008	 regarding	 the	
use	of	Schedule	8	drugs	(25).	Schedule	8,	or	S8,	drugs	
are defined as “substances which should be available 
for use but require restriction of manufacture, supply, 
distribution, possession and use to reduce abuse, misuse 
and	physical	or	psychological	dependence”	(26).	These	
are also referred to as drugs of addiction or drugs of de-
pendence	 (27),	and	 include	opioids,	 stimulants	 (meth-
ylphenidate	and	dexamphetamine),	and	flunitrazepam	
in	Western	Australia.
National Opioid Use Guideline Group 
(NOUGG, Canada)
The Canadian guideline, published in 2010, was de-
veloped	by	the	National	Opioid	Use	Guideline	Group	in	
Key Words Recommendation Grade*
Cluster 1: Deciding to initiate opioid therapy
Comprehensive 
assessment
Before initiating opioid therapy, ensure comprehensive documentation of the patient’s pain condition, general 
medical condition and psychosocial history (Grade C), psychiatric status, and substance use history. (Grade B).
B to C
Addiction-risk 
screening
Before initiating opioid therapy, consider using a screening tool to determine the patient’s risk for opioid 
addiction. 
B
Urine drug 
screening
When using urine drug screening (UDS) to establish a baseline measure of risk or to monitor compliance, be 
aware of benefits and limitations, appropriate test ordering and interpretation, and have a plan to use results. 
C
Opioid efficacy Before initiating opioid therapy, consider the evidence related to effectiveness in patients with chronic non-
cancer pain. 
A
Risks, adverse 
effects, 
complications
Before initiating opioid therapy, ensure informed consent by explaining potential benefits, adverse effects, 
complications and risks (Grade B). A treatment agreement may be helpful, particularly for patients not well 
known to the physician or at higher risk for opioid misuse. (Grade C).
B to C
Table 2. Recommendations from the Canadian NOUGG guideline.
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Key Words Recommendation Grade*
Benzodiazepine 
tapering
For patients taking benzodiazepines, particularly for elderly patients, consider a trial of tapering (Grade B). 
If a trial of tapering is not indicated or is unsuccessful, opioids should be titrated more slowly and at lower 
doses. (Grade C).
B to C
Cluster 2: Conducting an opioid trial
Titration and 
driving
During dosage titration in a trial of opioid therapy, advise the patient to avoid driving a motor vehicle until 
a stable dosage is established and it is certain the opioid does not cause sedation (Grade C); and when taking 
opioids with alcohol, benzodiazepines, or other sedating drugs. (Grade B).
B to C
Stepped opioid 
selection
During an opioid trial, select the most appropriate opioid for trial therapy using a stepped approach, and 
consider safety. 
C
Optimal doses When conducting a trial of opioid therapy, start with a low dosage, increase dosage gradually and monitor 
opioid effectiveness until optimal dose is attained. 
C
Watchful dose Chronic non-cancer pain can be managed effectively in most patients with dosages at or below 200 mg/day of 
morphine or equivalent (Grade A). Consideration of a higher dosage requires careful reassessment of the pain 
and of risk for misuse, and frequent monitoring with evidence of improved patient outcomes. (Grade C).
A to C
Risk: opioid misuse When initiating a trial of opioid therapy for patients at higher risk for misuse, prescribe only for well-
defined somatic or neuropathic pain conditions (Grade A), start with lower doses and titrate in small-dose 
increments (Grade B), and monitor closely for signs of aberrant drug-related behaviours. (Grade C).
A to C
Cluster 3: Monitoring long-term opioid therapy (LTOT)
Monitoring LTOT When monitoring a patient on long-term therapy, ask about and observe for opioid effectiveness, adverse 
effects or medical complications, and aberrant drug-related behaviours. 
C
Switching or 
discontinuing 
opioids
For patients experiencing unacceptable adverse effects or insufficient opioid effectiveness from one particular 
opioid, try prescribing a different opioid or discontinuing therapy. 
B
LTOT and driving When assessing safety to drive in patients on long-term opioid therapy, consider factors that could 
impair cognition and psychomotor ability, such as a consistently severe pain rating, disordered sleep, and 
concomitant medications that increase sedation. 
C
Revisiting opioid 
trial steps
For patients receiving opioids for a prolonged period who may not have had an appropriate trial of therapy, 
take steps to ensure that long-term therapy is warranted and dose is optimal. 
C
Collaborative care When referring patients for consultation, communicate and clarify roles and expectations between primary-
care physicians and consultants for continuity of care and for effective and safe use of opioids. 
C
Cluster 4: Treating specific populations with long-term opioid therapy
Elderly patients Opioid therapy for elderly patients can be safe and effective (Grade B) with appropriate precautions, including 
lower starting doses, slower titration, longer dosing interval, more frequent monitoring, and tapering of 
benzodiazepines. (Grade C).
B to C
Adolescent patients Opioids present hazards for adolescents (Grade B). A trial of opioid therapy may be considered for adolescent patients 
with well-defined somatic or neuropathic pain conditions when non-opioid alternatives have failed, risk of opioid 
misuse is assessed as low, close monitoring is available, and consultation, if feasible, is included in the treatment plan. 
C
Pregnant patients Pregnant patients taking long-term opioid therapy should be tapered to the lowest effective dose slowly 
enough to avoid withdrawal symptoms, and then therapy should be discontinued if possible.
B
Co-morbid 
psychiatric 
diagnoses
Patients with a psychiatric diagnosis are at greater risk for adverse effects from opioid treatment. Usually in 
these patients, opioids should be reserved for well-defined somatic or neuropathic pain conditions. Titrate 
more slowly and monitor closely; seek consultation where feasible. 
B
Cluster 5: Managing opioid misuse and addiction in chronic non-cancer pain (CNCP) patients
Addiction treatment 
options
For patients with chronic non-cancer pain who are addicted to opioids, three treatment options should be 
considered: methadone or buprenorphine treatment (Grade A), structured opioid therapy (Grade B), or 
abstinence-based treatment (Grade C). Consultation or shared care, where available, can assist in selecting 
and implementing the best treatment option. (Grade C).
A to C
Prescription fraud To reduce prescription fraud, physicians should take precautions when issuing prescriptions and work 
collaboratively with pharmacists.
C
Patient unacceptable 
behaviour
Be prepared with an approach for dealing with patients who disagree with their opioid prescription or exhibit 
unacceptable behaviour.
C
Acute-care opioid 
prescribing policy
Acute or urgent health care facilities should develop policies to provide guidance on prescribing opioids for 
chronic pain to avoid contributing to opioid misuse or diversion.
C
Table 2 (cont.). Recommendations from the Canadian NOUGG guideline.
*Recommendation grades: Grade A: consistent high-quality evidence. Grade B: inconsistent or limited evidence. Grade C: lacking direct evidence.
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collaboration with various Canadian medical societies, 
and consists of 24 evidence-based recommendations 
under	5	clusters	(Table	2),	each	representing	an	aspect	
of management, as summarized below. Each recom-
mendation statement is followed by a discussion and a 
summary of peer-reviewed evidence. 
While the document is organized topically rather 
than in a more step-wise fashion, the overall recom-
mendations nevertheless agree with the broad prin-
ciples	outlined	in	the	APS-AAPM	guideline	and	the	rest	
of the reviewed practice guidelines. Particular features 
of the Canadian guideline include a detailed discussion 
on urine drug screening, taken at baseline and used as 
a monitoring tool. 
The Canadian guideline also includes a specific 
recommendation and discussion on a trial of benzo-
diazepine tapering for patients with concomitant use 
of benzodiazepines, particularly in the elderly; the 
combination of opioids and benzodiazepines increases 
the risk of sedation, overdose, and diminished func-
tion	in	all	patients,	especially	as	age	advances	(28-30).	
This was also mentioned in the recommendations for 
the elderly, under the cluster of long-term therapy for 
specific populations (elderly, adolescent, pregnant, and 
psychiatric),	 which	 is	 another	 notable	 feature	 of	 the	
Canadian guideline.
British Pain Society
Also	 in	 2010,	 the	 British	 Pain	 Society	 published	
Opioids	for	Persistent	Pain:	Good	Practice	as	guidance	
for opioid use in chronic non-cancer pain. The British 
guideline is compatible with the recommendations in 
the	American	guidelines	regarding	patient	evaluation	
and risk assessment, use of opioid analgesics, and moni-
toring for adverse events and aberrant drug-related 
behavior.	 However,	 while	 the	 American	 guidelines	
placed particular emphasis on public health concerns, 
the British guideline adopted a more clinical approach 
in its recommendations, which were organized and dis-
cussed in the context of providing safe and appropriate 
relief from chronic pain. Treatment goals include not 
only reduction in pain intensity but also improvement 
in sleep, mood, and physical, vocational, social, and 
emotional wellbeing. 
The recommendations are presented not as a re-
view of scientific evidence, but as a practical guide on 
the appropriate evaluation and management of the 
patient in pain. The guidance briefly describes the basic 
pharmacology of currently available opioid analgesics 
and discusses the adverse effects of opioid therapy with 
recommendations for management, including advising 
patients to avoid driving at the start of opioid therapy 
and following dose changes. 
The document also provides general guidance on 
when to prescribe opioids and their appropriate choice. 
In particular, the guideline recommends that drugs with 
demonstrated efficacy for persistent pain syndromes 
(e.g., tricyclic antidepressants and antiepileptic drugs for 
neuropathic	 pain)	 should	 always	 be	 prescribed	 before	
starting opioids. The guideline further recommends us-
ing modified-release opioids administered at regular 
intervals, where possible; injectable opioids are not rec-
ommended except in extraordinary circumstances, and 
then only after consultation with a specialized multidisci-
plinary	pain	management	service.	As	with	the	APS-AAPM	
guideline, the British guideline recommends that a trial of 
opioid therapy be done to aid in the decision-making on 
whether to initiate long-term opioid therapy. 
American College of Occupational and 
Environmental Medicine (ACOEM)
The	 American	 College	 of	 Occupational	 and	 En-
vironmental	 Medicine	 (ACOEM)	 guideline	 was	 pub-
lished in 2011, in response to emerging evidence of 
an increased risk of death that appeared to parallel 
the increase in opioid consumption. It was developed 
to provide a framework for management of pain that 
had not been controlled by more conservative means, 
particularly in injured workers, and includes guidance 
for the initiation, maintenance, and discontinuation of 
opioid therapy, as well as criteria to diagnose addiction, 
substance	abuse,	and	problematic	opioid	use.	As	with	
the guidelines discussed above, it also adopts a bio-
psychosocial rather than a biomedical perspective, and 
advocates limiting chronic opioid therapy to patients 
in whom other proven treatments have failed and for 
whom opioids show continued clear documented ben-
efit. Table 3 outlines the evidence-based recommenda-
tions described in the document.
Similar to the British guideline, goals of treatment 
are more holistic and focus not only on pain reduction 
but also on health-related quality of life as measured 
by	 physical	 (disease-specific	 or	 generic)	 and	 emotional	
functioning; participant ratings of global improvement, 
symptoms, and adverse effects; and participant disposi-
tion	(i.e.,	adherence	to	the	treatment	regimen).		However,	
unlike the British guideline which does not have specific 
provisions for restricting opioid therapy on any particular 
patient	population,	 the	ACOEM	takes	a	more	conserva-
tive stance and proposes withholding opioid therapy in 
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patients with relevant behavioral and emotional issues 
until psychological evaluation and, if warranted, referral 
for appropriate psychological, behavioral, and/or reha-
bilitative interventions are carried out. The guideline also 
provides recommendations on the evaluation, manage-
ment, and potential weaning of patients who are already 
on opioid therapy, especially those who have not reported 
functional gains despite being maintained on high doses 
of extended-release opioids. 
Potential effects of opioid therapy on driving were 
discussed in greater detail, based on an evidence-based 
review to assess opioid-related impairment of driving 
skills. Results suggest that opioids do not impair driv-
ing-related skills in opioid-dependent/tolerant patients. 
Nevertheless,	while	 each	patient	 should	be	evaluated	
individually according to occupational or personal re-
quirements, the guidance cautions health care provid-
ers that prescribing opioids to patients who operate a 
commercial motor vehicle or pilot an aircraft generally 
precludes them from working, and other workers in 
safety-sensitive positions in industry (e.g., industrial 
machinery,	construction,	heavy	equipment	operations)	
who are prescribed opioids may be restricted from re-
turning to their jobs at the discretion of management.
American Society of Interventional Pain 
Physicians (ASIPP)
The	2012	ASIPP	guideline	was	published	in	part	as	
an	update	to	the	previous	ASIPP	guideline	published	in	
2008	and	presents	a	comprehensive	review	of	scientific	
literature, consensus among the panellists, and practice 
patterns, including references to previous guidelines 
published	 by	 the	 APS-AAPM,	 Canadian	 NOUGG,	 and	
British Pain Society. The guideline also features a man-
agement algorithm for opioid therapy that outlines 
the steps from initial patient assessment to treatment 
tapering or discontinuation, as well as algorithms for 
risk stratification, adherence monitoring, and urine 
drug	testing	(UDT).	
Like	the	British	guideline,	the	ASIPP	recommenda-
tions demonstrate a clinical approach, tracing a step-
wise path from initial patient assessment through final 
disposition (treatment continuation/ discontinuation/
modification).	 However,	 unlike	 the	 British	 guideline,	
the	 ASIPP	 offers	 evidence-based	 instead	 of	 practical	
recommendations. 
Compared with the 25 recommendations in the 
APS-AAPM	 guideline,	 most	 of	 which	 were	 strongly	
recommended despite the lack of strong scientific ev-
idence, a re-evaluation of scientific evidence for the 
current	ASIPP	guideline	yielded	fair	to	good	evidence	
for	 the	 majority	 of	 the	 27	 consensus	 recommenda-
tions that fall under 10 steps of opioid therapy (Table 
4).	The	ASIPP	determined	that	evidence	is	still	limited	
on the benefits of long-term therapy and the utility 
of opioid rotation, buprenorphine, or methadone for 
treatment modification; nevertheless, current evi-
dence does not appear to be in conflict with earlier 
recommendations. 
Recommendation Strength of  evidence
Routine use of opioids for chronic pain Not Recommended, Evidence (C)
Use of opioids for select patients with chronic persistent pain, neuropathic pain, or CRPS Recommended, Insufficient 
Evidence (I)
Screening for prior substance abuse and psychological evaluation Recommended, Insufficient 
Evidence (I)
Treatment agreement to document patient understanding and agreement with the expectations of opioid 
use 
*If literacy is a problem, the physician should read the agreement to the patient and ascertain that they 
understand it or revise the agreement so they can read and understand its content
Recommended, Insufficient 
Evidence (I)
Routine use of urine drug screening for patients on chronic opioids Recommended, Evidence (C)
Table 3. Evidence-based recommendations from the ACOEM guidelines.
Recommended, Evidence (C) – The intervention is recommended for appropriate patients. There is limited evidence that the intervention may 
improve important health and functional benefits.
Recommended, Insufficient Evidence (I) – Consensus-based; The intervention is recommended for appropriate patients and has nominal costs 
and essentially no potential for harm. The EBPP feels that the intervention constitutes best medical practice to acquire or provide information 
in order to best diagnose and treat a health condition and restore function in an expeditious manner. The EBPP believes based on the body of 
evidence, first principles, and/or collective experience that patients are best served by these practices, although the evidence is insufficient for an 
evidence-based recommendation.
Not Recommended, Evidence (C) – Recommendation against routinely providing the intervention. The EBPP found at least moderate evidence 
that harms and costs exceed benefits based on limited evidence.
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Step Recommendation Evidence
Initial steps of opioid 
therapy 
Comprehensive assessment and documentation before initiating opioid therapy Good
Screening for opioid use Limited
Implementation of prescription drug monitoring programs (PMDPs) Good to fair
Implementation of urine drug testing (UDT) along with subsequent adherence monitoring Good
Establish diagnosis Establishment of appropriate physical diagnosis and psychological diagnosis if available prior 
to initiating opioid therapy Good
Caution in ordering imaging and other evaluations, and providing patients only with 
appropriate relevant clinical information when there is correlation of the symptoms with 
findings 
Good
Pain management consultation, for non-pain physicians, if high-dose opioid therapy is being 
utilized Fair
Establishing medical 
necessity
Establishment of medical necessity prior to initiation or maintenance of opioid therapy Good
Establishing treatment goals Establishment of treatment goals of opioid therapy with regard to pain relief and 
improvement in function Good
Assessment of effectiveness 
of opioid therapy
Understanding the effectiveness and adverse consequences of long-term opioid therapy in 
chronic non-cancer pain and its limitations 
Fair for short-
term, limited 
for long-term
Use of high doses of long-acting opioids only in specific circumstances with severe intractable 
pain that is not amenable to short-acting or moderate doses of long-acting opioids Fair
Trial of opioid rotation for patients requiring escalating doses Limited
Evaluation of contraindications to opioid use in chronic non-cancer pain Fair to limited
Informed decision-making Development of a robust agreement which is followed by all parties for initiating and 
maintaining opioid therapy Fair
Initial treatment Once medical necessity is established, initiation of opioid therapy with low doses and short-
acting drugs with appropriate monitoring to provide effective relief and avoid side effects 
Fair for short-
term, limited 
for long-term 
effectiveness
Recommended doses of up to 40 mg of morphine equivalent doses as low dose, 41 to 90 
mg of morphine equivalent dose as a moderate dose, and greater than 91 mg of morphine 
equivalence as high dose 
Fair
Caution in titration of long-acting opioids Good
Use of methadone in late stages after failure of other opioid therapy and only by clinicians 
with specific training in the risks and uses Limited
Adherence monitoring Obtaining an electrocardiogram prior to initiation, at 30 days and yearly thereafter for 
monitoring methadone prescription Fair
Adherence monitoring by UDT and PMDPs to identify non-compliant patients or 
prescription drugs or illicit drug abuse Fair
Monitoring and managing 
side effects
Monitoring for and appropriate management of side effects, including discontinuation of 
opioids if indicated Fair
Close monitoring for constipation and initiation of a bowel regimen as soon as deemed 
necessary Good
Development and monitoring of a policy for driving under the influence of drugs during 
initiation of therapy, changes in the dosages, and addition of other centrally acting agents Good
The final phase Continuation of chronic opioid therapy with continuous adherence monitoring, modified 
at any time during this phase, in conjunction with or after failure of other modalities of 
treatments with improvement in physical and functional status and minimal adverse effects. 
Fair
Use of methadone and buprenorphine in late stages after failure of other opioid therapy and 
only by clinicians with specific training in the risks and uses Limited
A trial of opioid rotation for patients requiring escalating doses. Limited
Monitoring of chronic opioid therapy for adverse effects, with appropriate management Good
Table 4.  ASIPP recommendations with evidence levels.
PMDP = prescription drug monitoring program; UDT = urine drug testing
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Pain Association of Singapore
The treatment guideline published by the Pain 
Association	 of	 Singapore	 is	 the	 most	 recent	 of	 the	
guidelines reviewed in this document. The general 
recommendations on approach to opioid therapy are 
consistent with those in the guidelines discussed above: 
detailed patient evaluation; risk assessment and special-
ist referral as needed; informed consent; trial of opioid 
therapy prior to initiation of therapy; use of minimum 
effective dose with upward titration as needed and as 
tolerated; patient monitoring for aberrant behavior, 
adverse effects, or loss of efficacy; and dose tapering 
and discontinuation, as needed. 
In addition to guidance on the approach to overall 
management, the Singapore guideline also provides 
specific evidence-based treatment recommendations for 
low back pain, neck pain, musculoskeletal pain, head/
orofacial pain, chronic pelvic pain, persistent post-surgi-
cal pain, fibromyalgia, post-herpetic neuralgia, diabetic 
peripheral neuropathic pain, and peripheral vasculopa-
thy. Review of evidence suggests that opioids may be 
used for pain relief if other analgesics are ineffective, 
or as part of a multimodal treatment regimen; however, 
overall, evidence to support long-term opioid use is still 
limited.	 Nonetheless,	 there	 is	 evidence	 to	 support	 the	
benefits of tramadol in low back pain, fibromyalgia, and 
post-surgical pain; the short-term benefits of oxycodone 
in neck pain; and opioid monotherapy in diabetic pe-
ripheral neuropathic pain and peripheral vasculopathy. 
The use of pethidine is not recommended due to its high 
potential for abuse and risk of neurotoxicity.
discussion
Guidelines on the use of opioid analgesics for 
chronic pain were developed for various reasons. The 
Singapore guideline was developed in response to the 
increasing	 incidence	 of	 chronic	 pain	 in	 Asia,	 owing	 in	
part to the increasing size of the elderly population (> 65 
years).	In	the	UK,	Australia,	and	New	Zealand,	the	major-
ity of chronic pain cases are managed by general prac-
titioners,	and	the	British	Pain	Society	and	Australia	and	
New	Zealand	College	of	Anaesthetists	 (ANZCA)	guide-
lines were consequently developed by multidisciplinary 
panels as a general guide for all health care professionals 
who manage chronic pain. In an effort to provide more 
evidence-based guidelines on the rational use of opioids 
for	 chronic	 pain,	 the	APS-AAPM	and	NOUGG	 released	
more	 comprehensive	 recommendations	 in	 the	 United	
States	and	Canada,	 respectively.	The	ACOEM	guideline	
was published especially as a guide for managing injured 
workers whose pain is not controlled by more conserva-
tive	therapy.	More	recently,	the	ASIPP	built	on	previously	
published	guidelines,	 including	those	from	the	US,	UK,	
and Canada, and updated with new evidence at the time 
of development. The current document aims to provide 
a concise review of current expert-developed guidelines, 
as a useful reference both for current practice and for fu-
ture development of opioid guidelines in other regions.
While there is some variation in the focus and level 
of detail of practice guidelines across different coun-
tries and specialities, the following general principles 
governing the approach to initiating opioid therapy 
were	noted	across	all	guidelines	(Table	5).
1.	 A	comprehensive	evaluation,	with	particular	emphasis	
on psychological, psychosocial, and other factors that 
may help identify potential drug misuse and abuse, 
should be conducted as part of the initial assessment 
of the patient with chronic non-cancer pain. 
2. Prior to initiating therapy, a trial of opioid therapy is 
recommended to aid decision-making on whether or 
not to proceed with the opioid treatment regimen. 
3. Patients should be adequately informed of the 
benefits	 and	 risks	 of	 opioid	 therapy.	 Obtaining	
written and signed informed consent prior to initi-
ating therapy may be appropriate in some cases.
4.	 Opioids	 are	 generally	 not	 recommended	 as	 first-
line therapy, and must be considered only when 
other evidence-based interventions are unavail-
able or ineffective. 
5. The treatment regimen, including opioid selection 
and dosage, should be individualized according to 
patient needs and response.
6. Patients should be started at the minimum dose 
required to effect relief without significant adverse 
effects, and the dose subsequently titrated upward 
according to patient response and safety.
7.	 Once	 therapy	 is	 initiated,	 the	 patient	 must	 be	
closely monitored for loss of response, adverse 
events, or aberrant drug-related behavior.
Driving while on opioid therapy was discussed with 
varying levels of detail across guidelines. In general, 
evidence suggests that opioid therapy does not impair 
driving skills; however, it may be prudent to avoid driv-
ing at the start of therapy or dose adjustment, or when 
impaired cognitive functioning is noted or suspected. 
Other	principles	relevant	to	long-term	opioid	therapy,	
emphasized to varying degrees across different guide-
lines, are discussed below. 
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ANZCA APS-AAPM NOUGG BPS ACOEM ASIPP PAS
Patient 
evaluation
All guidelines advocate comprehensive patient evaluation, with particular emphasis on identifying risk factors for adverse events and drug 
misuse
Informed 
consent
Yes Yes Yes No mention Yes; sample 
treatment 
agreement form 
provided
Yes; sample 
treatment 
agreement form 
provided
Yes, preferably 
with a signed 
opioid treatment 
agreement
Trial of 
opioid 
therapy
Based on 
individual 
assessment 
Yes, for several 
weeks to months
Yes; stepped 
approach to 
selecting opioids 
described in 
guideline
No specific dosing 
recommendations
No specific dosing 
recommendations
No specific 
discussion
Yes, up to 2 
months
Optimal 
starting 
dose
No specific dose 
recommendations
Based on 
individual 
assessment
Suggested initial 
doses provided 
in Table B-9.1 of 
the guideline
Not specified No specific dose 
recommendations
Suggested doses 
provided in Table 
7 of the guideline
Based on 
individual 
assessment
Opioids as 
first-line 
therapy
Not recommended Not 
recommended
Stepped 
approach 
described in 
Table B-8.1 of 
the guideline
Not 
recommended
Not 
recommended
No specific 
recommendation
Not generally 
recommended
Driving 
while on 
opioid 
therapy
No specific 
recommendation
Caution, 
especially when 
initiating or 
changing doses
Caution, 
especially at start 
of opioid trial
Caution, 
especially at start 
of opioid therapy 
and following 
dose changes
Based on 
individual 
evaluation 
Caution, 
especially during 
dosage titration
No mention
Methadone No specific 
recommendation
For experienced 
clinicians only; 
use with caution 
May consider in 
opioid addiction 
Caution in 
pregnant women
No specific 
recommendation; 
risks mentioned 
May consider 
after failure of 
opioid therapy; 
for experienced 
clinicians only
No specific 
recommendation
Opioid 
rotation
May be considered 
to address 
inappropriate 
response to 
current opioid 
Consider for 
inadequate 
benefit or 
intolerable side 
effects
Start new opioid 
on lower dose 
(50%-75% less 
than previous, 
converted to 
morphine 
equivalent)
No mention No mention Consider in 
patients requiring 
escalating doses
No  specific 
recommendation
Urine drug 
testing
May be included 
as a monitoring 
tool in the 
treatment plan
For patients at 
high risk or who 
have exhibited 
aberrant 
behaviour
To establish 
baseline, 
monitor 
compliance
No mention Routine screening 
recommended
Must be 
implemented 
from initiation of 
therapy
Recommended 
in all high-risk 
patients
Maximum 
daily dose
Doses above the 
equivalent of 120 
mg morphine 
per day require 
reassessment 
including 
specialist advice if 
possible
No specific 
recommendation
Exercise 
particular 
caution when 
prescribing 
doses exceeding 
200 mg 
morphine 
equivalent
Refer to specialist 
for doses 
exceeding 120-
180 mg morphine 
equivalent
No mention low-dose: ≤ 40 
mg; 
moderate dose: 
41-90 mg; high 
dose: ≥ 91 
mg morphine 
equivalent 
dosages
Consider 
discontinuation 
for doses ≥ 200 
mg morphine 
equivalent
Table 5. Comparison of  recommendations on selected parameters.
Trial of opioid therapy and optimal starting 
dose
A	trial	of	opioid	therapy	is	recommended	not	just	
to determine whether or not to proceed with opioid 
therapy; a trial of therapy is also used to determine 
optimal dose. For this reason, most of the guidelines do 
not recommend specific starting doses, instead recom-
mending that these be determined based on individual 
evaluation. The selection of which opioid to use may 
be based on pain severity, prior exposure to opioids, or 
even cost. Codeine appears to be an appropriate first-
line agent for mild to moderate pain, while morphine 
is a common initial choice for severe pain, along with 
oxycodone	or	hydromorphone	(1,19,22,31).	
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Theoretical considerations can also influence the 
choice	of	starting	agent;	while	the	Australian	and	New	
Zealand	guidelines	emphatically	discourage	the	use	of	
short-acting opioids as initial therapy and recommend 
the	use	of	long-acting	opioids,	the	ASIPP	believes	that	
long-acting opioids have a greater potential for abuse 
because they tend to be provided in high-dose formula-
tions and can easily induce immediate-release effects 
when	bitten	or	crushed;	thus,	the	ASIPP	guideline	spe-
cifically recommends initiating therapy with low doses 
of short-acting opioids. 
Despite apparent differences in the recommenda-
tions on opioid initiation and maintenance, all guide-
lines	echo	the	principles	of	the	WHO	analgesic	 ladder	
(32),	which	was	developed	as	a	guide	for	cancer	pain	
but	may	also	apply	to	chronic	non-cancer	pain	(33).	 It	
is also clear that thorough history-taking and patient 
evaluation is crucial in determining the appropriate 
agent	and	dose	for	each	patient.	Once	initiated,	opioid	
therapy must then be followed by careful patient moni-
toring for adequacy and appropriateness of response.
Maximum dose 
Upper	 threshold	 levels	 for	daily	doses	of	morphine	
or morphine equivalents differ slightly for each guideline, 
as well as recommended further steps once the threshold 
is	reached.	The	South	Australian	guideline	sets	different	
maximum doses for different drugs and recommends 
referral to a pain specialist for unusual dose requirements 
(27),	 a	 recommendation	adopted	by	 the	ANZCA	guide-
line. Similarly, the British guideline strongly recommends 
referral to a pain medicine specialist if useful relief from 
pain	symptoms	is	not	achieved	at	daily	doses	of	120	–	180	
mg	morphine	equivalent.	On	 the	other	hand,	both	 the	
Canadian and Singapore guidelines set a threshold daily 
morphine or equivalent dose of 200 mg; yet, while the 
Singapore guideline recommends considering discontinu-
ation if therapeutic goals are not achieved at this dose, the 
Canadian guideline sets 200 mg daily only as a “watchful 
dose,” above which patients must be monitored more 
frequently for opioid effectiveness, medical complica-
tions,	adverse	effects,	and	risks.	The	American	guidelines	
provided	no	specific	recommendations;	at	most,	the	ASIPP	
guideline assigned daily morphine or equivalent doses 
below	41	mg	as	low	and	above	91	mg	as	high	dose,	with	
in-between doses classified as moderate. In the absence 
of a clear consensus, 100 to 120 mg morphine equivalent 
seems to be a prudent reference level for heightened cau-
tion	(34,35),	due	to	evidence	of	increased	morbidity	and	
mortality	at	these	doses	(2,7,36).	
Methadone 
Methadone is a long-acting synthetic opioid that 
has been available for more than 50 years. Its widely 
variable	 half-life	 (37)	makes	 universal	 dosing	 recom-
mendations difficult; nevertheless, its relatively low 
cost, powerful effect, and long duration of action 
have probably contributed to its increased use for 
chronic	 pain	 in	 recent	 years	 (38).	 This	 increase	 has	
been paralleled by increases in methadone abuse 
and	 methadone-related	 deaths	 in	 the	 United	 States	
(39-41),	 which	 may	 account	 for	 the	 more	 conserva-
tive	 stance	 of	 the	 American	 guidelines	 regarding	
methadone	use.	American	hesitancy	notwithstanding,	
methadone still has a place in pain management, es-
pecially in the treatment of opioid addiction, and is 
still considered an acceptable option for chronic pain. 
Although	 non-American	 guidelines	 do	 not	 actively	
discourage the use of methadone, particular care in 
determining appropriate doses for each patient is 
recommended, taking into consideration the patient’s 
individual response to the drug.  
Opioid rotation
Opioid	 rotation	 refers	 to	a	 switch	 from	one	opioid	
to another. It is a common strategy to address tolerance, 
achieve increased analgesic response, and help manage 
side	effects	during	opioid	therapy	(42),	usually	with	the	
use of an equianalgesic dose table as basis for determining 
the	dose	of	the	new	opioid	(27).	However,	a	recent	review	
of opioid rotation practices has revealed an increase in 
fatal or near-fatal overdoses that could be due to errors in 
prescribing, such as inappropriate dose conversion ratios 
in	equianalgesic	tables	(43).	To	minimize	risk	of	overdos-
ing, a starting dose lower than the calculated equianal-
gesic dose is recommended, with subsequent titration to 
optimize the balance between pain relief and side effects. 
The Canadian guideline recommends starting the new 
opioid	on	50%	to	75%	less	than	the	previous	morphine	
equivalent	 dose;	 the	 APS-AAPM	 and	 ASIPP	 guidelines	
likewise allow opioid rotation as an option in cases of 
inadequate response or intolerable adverse effects, but 
provide no specific dosing recommendations. 
Urine drug testing 
UDT	 is	 useful	 in	 identifying	 aberrant	 behavior	
or drug misuse, and may be conducted to establish 
a baseline measure and to monitor compliance. The 
Canadian guideline suggests that there may be a role 
for	UDT	to	establish	a	baseline	measure	of	risk	or	to	
monitor	 compliance.	 Nevertheless,	 the	 ASIPP	 guide-
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line	 takes	 a	 firmer	 position	 on	 UDT,	 recommending	
routine	UDT	not	only	to	identify	patients	taking	illicit	
substances but also to de-stigmatize drug testing. In 
fact, there is no compelling evidence to guide physi-
cians	on	 identifying	which	patients	 should	have	UDT	
or how often. Clinicians are advised to consider the 
patient’s risk for opioid misuse and addiction, aber-
rant	 drug-related	behaviors,	 and	 availability	 of	UDT.	
Instituting	 routine	UDT	may	 circumvent	 the	 need	 to	
identify	candidates	for	and	frequency	of	UDT;	further,	
routine	UDT	may	 ease	 the	 perceived	 lack	 of	 trust	 in	
the	patient	when	a	UDT	is	requested,	and	can	help	de-
stigmatize drug testing while providing a complement 
to self-reporting and behavioral monitoring to detect 
drug	 abuse	 and	misuse	 (19,22,44).	 Regardless	 of	 the	
decision	on	whether	to	request	UDT	for	all	or	selected	
patients, clinicians are cautioned to be aware of the 
benefits	and	limitations	of	UDT	as	well	as	appropriate	
test ordering and interpretation, and have a plan in 
place on how to use the results.  
conclusion
The substantial increase in the use of opioids 
for pain not associated with malignant disease or 
end-of-life care has encouraged the development 
of a wealth of information on the appropriate use 
of opioids for chronic non-cancer pain. Experts and 
specialty organizations from several countries have 
developed guidance documents to help patients and 
health care providers navigate the benefits and risks 
associated with opioid analgesic therapy. This review 
of recently published guidelines revealed a broad 
commonality across guidelines in the basic principles 
governing the responsible use of opioid analgesics, 
which include careful patient evaluation, gradual 
dose titration, and close monitoring. Taken individu-
ally, each guideline presents a different perspective 
that provides additional details to complement the 
general	 principles.	 	 The	 2012	 ASIPP	 guidelines	 sug-
gest that scientific evidence to support general 
recommendations has become more robust recently, 
compared with the scientific data available during 
the	development	of	the	2009	APS-AAPM	guidelines.	
Future directions should focus on continuing to 
generate good-quality evidence on the benefits of 
long-term opioid therapy, as well as scientific data to 
guide drug choice and dosing for specific conditions, 
populations, and situations.   
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